Respiratory System Drugs Practice Questions

Q: How do antihistamines help in allergic rhinitis?

block histamine receptors to reduce symptoms.. **Correct Answer: Block histamine receptors to reduce symptoms.** - Antihistamines work by competitively binding to **histamine H1 receptors**, preventing histamine from exerting its effects. - This action directly reduces symptoms such as **sneezing**, **itching**, and **rhinorrhea** (runny nose) associated with allergic reactions. - They act after histamine has been released by blocking its receptors on target tissues. *Incorrect: Inhibit prostaglandin synthesis to relieve itching.* - This mechanism of action is characteristic of **NSAIDs (non-steroidal anti-inflammatory drugs)**, which primarily target pain and inflammation, not the histamine-mediated symptoms of allergic rhinitis. - While prostaglandins can contribute to inflammation, antihistamines do not act on their synthesis. *Incorrect: Reduce inflammation by blocking leukotrienes.* - This mechanism describes the action of **leukotriene receptor antagonists** (e.g., Montelukast), which are used in asthma and allergic rhinitis but are distinct from antihistamines. - Leukotrienes are potent inflammatory mediators, and blocking them helps reduce inflammation and bronchoconstriction. *Incorrect: Prevent the release of mast cell mediators.* - This is the mechanism of **mast cell stabilizers** (e.g., cromolyn sodium), which prevent the degranulation of mast cells and the subsequent release of histamine and other inflammatory mediators. - Antihistamines act after histamine has already been released, not before.

Q: How do corticosteroids reduce symptoms of allergic rhinitis?

reduce inflammation by inhibiting phospholipase A2.. ***reduce inflammation by inhibiting phospholipase A2*** - Corticosteroids exert their anti-inflammatory effects by inhibiting **phospholipase A2**, an enzyme crucial for releasing arachidonic acid from cell membranes. - This inhibition in turn prevents the synthesis of various inflammatory mediators, including **prostaglandins** and **leukotrienes**, thereby reducing the symptoms of allergic rhinitis. *inhibit histamine release from mast cells.* - While corticosteroids can stabilize mast cell membranes over time, their primary mechanism of action in allergic rhinitis is not the direct, immediate inhibition of **histamine release**. - **Antihistamines** are specifically designed to block the effects of histamine or reduce its release. *decrease prostaglandin production.* - Corticosteroids do decrease **prostaglandin production**, but this is a *downstream effect* of their inhibition of phospholipase A2, which is the more direct and overarching mechanism. - Non-steroidal anti-inflammatory drugs (NSAIDs) primarily inhibit **cyclooxygenase (COX) enzymes** to reduce prostaglandin synthesis. *block leukotriene receptors.* - Blocking **leukotriene receptors** is the mechanism of action for **leukotriene receptor antagonists** (e.g., montelukast), not corticosteroids. - Corticosteroids reduce the *production* of leukotrienes by inhibiting phospholipase A2, rather than directly blocking their receptors.

Q: Which beta-2 agonist bronchodilator is commonly used as a first-line therapy for managing acute asthma symptoms?

Salbutamol. ***Salbutamol*** - **Salbutamol** (also known as albuterol in some countries) is a **short-acting beta-2 agonist (SABA)** that provides rapid bronchodilation. - Its quick onset of action makes it ideal for the **first-line treatment of acute asthma symptoms** and exercise-induced bronchospasm. *Formoterol* - **Formoterol** is a **long-acting beta-2 agonist (LABA)** with a rapid onset of action, but it is typically used for **maintenance therapy** in combination with an inhaled corticosteroid, not as a rescue inhaler alone. - Using a LABA like formoterol as a monotherapy for acute symptoms without an inhaled steroid can be associated with increased risk of severe asthma exacerbations. *Salmeterol* - **Salmeterol** is another **long-acting beta-2 agonist (LABA)** that has a slower onset of action compared to salbutamol and formoterol. - It is used for **maintenance therapy** to prevent asthma symptoms and is not suitable for the immediate relief of acute asthma attacks. *Terbutaline* - **Terbutaline** is a **short-acting beta-2 agonist (SABA)** that can be used for acute asthma symptoms, similar to salbutamol. - However, **salbutamol** is generally the more commonly prescribed and widely recognized SABA for first-line acute asthma management in India.

Q: A patient with chronic obstructive pulmonary disease (COPD) is prescribed a phosphodiesterase-4 inhibitor to reduce the risk of exacerbations. Which drug is most likely being prescribed?

Roflumilast. ***Roflumilast*** - **Roflumilast** is a selective **phosphodiesterase-4 (PDE-4) inhibitor** approved specifically for reducing the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. - Its mechanism of action involves increasing intracellular **cAMP**, leading to reduced inflammation and smooth muscle relaxation in the airways. *Theophylline* - Theophylline is a **non-selective phosphodiesterase inhibitor** with a narrow therapeutic index and significant side effects, making it a less preferred option for routine exacerbation prevention [1], [2]. - While it has bronchodilator and anti-inflammatory effects through PDE inhibition, it is not a selective PDE-4 inhibitor [1]. *Salmeterol* - **Salmeterol** is a **long-acting beta-2 agonist (LABA)**, which primarily acts by bronchodilation, not through phosphodiesterase inhibition [1]. - It works by stimulating beta-2 adrenergic receptors in the airways, leading to smooth muscle relaxation. *Ipratropium* - **Ipratropium** is a **short-acting muscarinic antagonist (SAMA)** that works by blocking muscarinic receptors in the airways, leading to bronchodilation [2]. - It does not exert its effects through phosphodiesterase inhibition.

Q: In evaluating a new drug for asthma that targets muscle relaxation, which parameter would best indicate its efficacy during a clinical trial?

Improved FEV1/FVC ratio. ***Improved FEV1/FVC ratio*** - A drug targeting muscle relaxation in asthma aims to reduce **bronchoconstriction**, thereby improving airflow. - The **FEV1/FVC ratio** is a direct measure of **airflow obstruction** and reversibility, making it a primary indicator of improved lung mechanics. *Decreased frequency of asthma attacks* - While a desirable outcome, this parameter is often influenced by multiple factors beyond immediate bronchodilation, such as long-term disease control and patient adherence. - It's a **clinical outcome** rather than a direct physiological measure of acute bronchodilatory efficacy. *Reduction in diurnal peak flow variability* - This parameter reflects the **stability of airway inflammation** and responsiveness over a 24-hour period, which is more relevant to long-term disease control and corticosteroid efficacy. - It is an important indicator of asthma control but not the most direct measure of acute **bronchodilator efficacy** from muscle relaxation. *Lower serum IgE levels* - Serum IgE levels are primarily associated with the **allergic component of asthma** and are targeted by therapies like anti-IgE antibodies (e.g., omalizumab). - A drug focused on muscle relaxation would not directly impact **IgE production** or levels.

Q: Which of the following is a leukotriene receptor antagonist used in the management of asthma?

Montelukast. ***Correct Answer: Montelukast*** - **Montelukast** is a selective and orally active **leukotriene receptor antagonist** that specifically blocks the cysteinyl leukotriene 1 (CysLT1) receptor. - By blocking leukotrienes, it helps to **reduce inflammation**, bronchoconstriction, and mucus secretion, thus preventing asthma symptoms. - It is particularly useful for **exercise-induced asthma** and as an add-on therapy to inhaled corticosteroids. *Incorrect: Albuterol* - **Albuterol** is a **short-acting beta-2 adrenergic agonist (SABA)**, primarily used as a **rescue inhaler** for acute asthma symptoms. - It works by **relaxing the smooth muscles** in the airways, leading to bronchodilation, but does not target leukotrienes. *Incorrect: Fluticasone* - **Fluticasone** is an **inhaled corticosteroid (ICS)**, a cornerstone of long-term asthma control. - It reduces airway inflammation by **suppressing the immune response** at a cellular level, rather than blocking leukotriene receptors. *Incorrect: Salmeterol* - **Salmeterol** is a **long-acting beta-2 adrenergic agonist (LABA)**, used for long-term asthma control in combination with an inhaled corticosteroid. - It provides prolonged bronchodilation by **stimulating beta-2 receptors**, but does not act on leukotriene pathways.

Q: Which bronchodilator drug is considered the first-line therapy for acute asthma attacks due to its rapid onset of action?

Salbutamol. ***Salbutamol*** - **Salbutamol** is a **short-acting beta-2 agonist (SABA)**, which means it rapidly relaxes the smooth muscles of the airways [1], [4]. - Its **quick onset of action** (within minutes) makes it the preferred drug for immediate relief of **acute asthma symptoms** like shortness of breath and wheezing [1], [3]. *Salmeterol* - **Salmeterol** is a **long-acting beta-2 agonist (LABA)**, providing bronchodilation for up to 12 hours [5]. - It is used for **maintenance therapy** to prevent asthma attacks, not for acute relief, and should always be used in combination with an inhaled corticosteroid. *Ipratropium* - **Ipratropium** is a **short-acting anticholinergic** that blocks muscarinic receptors in the airways, leading to bronchodilation [2]. - While it can be used as an **adjunct to SABAs** in severe acute asthma, it has a slower onset of action and is not considered first-line monotherapy for acute attacks. *Tiotropium* - **Tiotropium** is a **long-acting anticholinergic** primarily used for the maintenance treatment of **COPD** and sometimes as an add-on therapy for severe asthma [5]. - Its **slow onset** and prolonged action make it unsuitable for the immediate relief of acute asthma symptoms.

Q: A 45-year-old man with chronic obstructive pulmonary disease (COPD) is experiencing worsening symptoms despite using short-acting bronchodilators. Which long-acting beta-agonist could be recommended for maintenance therapy?

Salmeterol. ***Salmeterol*** - Salmeterol is a **long-acting beta-agonist (LABA)**, indicated for maintenance therapy in COPD due to its prolonged bronchodilatory effect. - LABAs like salmeterol are crucial for **symptom control and reducing exacerbations** in patients with persistent COPD symptoms. *Albuterol* - Albuterol is a **short-acting beta-agonist (SABA)**, primarily used for **rescue relief** of acute bronchospasm, not for maintenance therapy. - Its effects last for only 4-6 hours, making it unsuitable for sustained symptom control in COPD. *Pirbuterol* - Pirbuterol is also a **short-acting beta-agonist (SABA)**, similar to albuterol, providing quick but temporary relief. - It is not recommended for daily, long-term maintenance treatment of COPD. *Orciprenaline* - Orciprenaline is an older, **short-acting beta-agonist** no longer commonly used due to a less favorable side effect profile and shorter duration of action. - It is not considered a modern first-line treatment for either acute relief or maintenance in COPD.

Q: Advantage of formoterol over salmeterol is?

It has got a faster onset of action. ***It has got a faster onset of action*** - **Formoterol** has a **faster onset of action** (within 1-3 minutes) compared to salmeterol, making it suitable for both maintenance and quick relief of bronchoconstriction. - This rapid onset allows it to act similarly to short-acting beta-agonists (SABAs) for symptom control, while also providing long-acting benefits. *Both can be used for prophylaxis in asthmatics* - While both **formoterol** and **salmeterol** are **long-acting beta-2 agonists (LABAs)** [1] and are used for prophylaxis (maintenance therapy) in asthma, this statement does not highlight an advantage of formoterol over salmeterol. - Their primary role is in preventing symptoms, not necessarily in acute relief due to this shared characteristic. *It is a long-acting beta 2 agonist* - Both **formoterol** and **salmeterol** are **long-acting beta-2 agonists** [1]. - This is a shared characteristic and not a unique advantage of formoterol over salmeterol. *It has minimal beta 1 agonistic action* - Both **formoterol** and **salmeterol** are *highly selective* for **beta-2 receptors** [1], meaning they both have minimal beta-1 agonistic action. - Therefore, this is not a distinguishing advantage of formoterol over salmeterol.

Q: In which condition is the use of PGF2α analogues contraindicated?

Bronchial asthma. ***Bronchial asthma*** - PGF2α analogues, particularly **carboprost**, are **uterotonics** that can cause **bronchoconstriction** and are thus contraindicated in patients with **bronchial asthma**. - This effect is due to the activation of prostanoid receptors in the airways, leading to the constriction of bronchial smooth muscle. *Postpartum hemorrhage* - **PGF2α analogues** like **carboprost** are frequently used to treat **postpartum hemorrhage** due to their potent uterotonic effects, which help to contract the uterus and stop bleeding. - This condition is an **indication**, not a contraindication, for PGF2α analogue use. *Glaucoma* - **Prostaglandin analogues** (e.g., latanoprost, travoprost), which are often PGF2α derivatives, are a **first-line treatment for glaucoma** as they effectively lower **intraocular pressure**. - Therefore, glaucoma is an **indication** for some PGF2α analogues, not a contraindication. *Priapism* - **PGF2α analogues** are generally **not directly implicated in the treatment or contraindication of priapism**, which is often managed with alpha-agonists, aspiration, or surgical shunts. - While prostaglandins (like PGE1) can induce erections, PGF2α analogues are not typically used in this context and do not pose a direct contraindication for priapism.

Question 1

How do antihistamines help in allergic rhinitis?

Accepted Answer

block histamine receptors to reduce symptoms.

Answer

inhibit prostaglandin synthesis to relieve itching.

Answer

reduce inflammation by blocking leukotrienes.

Answer

prevent the release of mast cell mediators.

Question 2

How do corticosteroids reduce symptoms of allergic rhinitis?

Accepted Answer

reduce inflammation by inhibiting phospholipase A2.

Answer

inhibit histamine release from mast cells.

Answer

decrease prostaglandin production.

Answer

block leukotriene receptors.

Question 3

Which beta-2 agonist bronchodilator is commonly used as a first-line therapy for managing acute asthma symptoms?

Accepted Answer

Salbutamol

Answer

Salmeterol

Answer

Formoterol

Answer

Terbutaline

Question 4

A patient with chronic obstructive pulmonary disease (COPD) is prescribed a phosphodiesterase-4 inhibitor to reduce the risk of exacerbations. Which drug is most likely being prescribed?

Accepted Answer

Roflumilast

Answer

Theophylline

Answer

Salmeterol

Answer

Ipratropium

Question 5

In evaluating a new drug for asthma that targets muscle relaxation, which parameter would best indicate its efficacy during a clinical trial?

Accepted Answer

Improved FEV1/FVC ratio

Answer

Decreased frequency of asthma attacks

Answer

Reduction in diurnal peak flow variability

Answer

Lower serum IgE levels

Question 6

Which of the following is a leukotriene receptor antagonist used in the management of asthma?

Accepted Answer

Montelukast

Answer

Albuterol

Answer

Fluticasone

Answer

Salmeterol

Question 7

Which bronchodilator drug is considered the first-line therapy for acute asthma attacks due to its rapid onset of action?

Accepted Answer

Salbutamol

Answer

Salmeterol

Answer

Ipratropium

Answer

Tiotropium

Question 8

A 45-year-old man with chronic obstructive pulmonary disease (COPD) is experiencing worsening symptoms despite using short-acting bronchodilators. Which long-acting beta-agonist could be recommended for maintenance therapy?

Accepted Answer

Salmeterol

Answer

Albuterol

Answer

Pirbuterol

Answer

Orciprenaline

Question 9

Advantage of formoterol over salmeterol is?

Accepted Answer

It has got a faster onset of action

Answer

Both can be used for prophylaxis in asthmatics

Answer

It is a long-acting beta 2 agonist

Answer

It has minimal beta 1 agonistic action

Question 10

In which condition is the use of PGF2α analogues contraindicated?

Accepted Answer

Bronchial asthma

Answer

Glaucoma

Answer

Priapism

Answer

Post partum hemorrhage

Respiratory System Drugs — MCQs

Respiratory System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?